Midazolam and drug–drug interactions in dental conscious sedation

摘要

Midazolam is an imidazobenzodiazepine,udwhich was first synthesised in 1976 by Fryerudand Walser. Its favourable properties includeuda reduced half life, high lipophilicity and a pHudof 3.5, which enables it to be water soluble inudthe preparatory ampoule. This subsequentlyudallowed for painless intravenousudadministration, in contrast with diazepam,udwhere thrombophlebitis had beenudcommonly reported at the site ofudadministration. Midazolam soon became anudalternative to diazepam and soon supersededudit as the mainstay pharmacological agent forudintravenous sedation. It has a therapeuticudrange of between 2mg and 7mg whenudadministered intravenously.1